TrialCancer immunology, immunotherapy : CII2015

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.

Joseph P Balint et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.